Business Wire

CSG Wins Business Impact Honor at TM Forum Catalyst Awards

18.4.2023 16:30:00 EEST | Business Wire | Press release

Share

CSG® (NASDAQ: CSGS) today announced that it was selected as a winner in the 2023 TM Forum Catalyst Awards. The awards celebrate the most successful innovation of the telecoms industry, proof-of-concepts for industry standards, and impact on sustainability goals. Conducted in participation with Microsoft, Nokia, and Vodafone, the CSG Channels & Markets Phase II project was recognized as an Outstanding Catalyst for Business Impact.

“Dynamic marketplaces present many opportunities for CSPs in B2B and B2B2X sectors, where cross-functional collaboration has become the new currency for success,” said Greg Tilton, VP of catalog, quote & order, CSG. “Collaboration is critical, which is why CSG joined forces with Microsoft, Nokia and Vodaphone to enable CSPs to capture new market segments beyond connectivity and thrive. We're honored to receive this recognition, and I extend a big thank you to our partners for the success we’ve achieved with the TM Forum Channel & Markets Phase II Catalyst."

The Catalyst project proves the capabilities of TM Forum Open APIs to support exposure across all channels for providers in and outside a B2B2X ecosystem. It simplifies the creation of dynamic B2B2X marketplaces so that CSPs can seamlessly bundle and market products that tap the powerful capabilities of third-party suppliers. Thanks to its zero-code design, it also enables a faster time to market, providing a competitive advantage in a dynamic field. This second phase of the Catalyst introduces new configurable components to TM Forum Open APIs with four main objectives:

  • Remove catalog barriers to unlock powerful new B2B2X business models.
  • Introduce configurable domain-specific service specifications to support connectivity and non-connectivity services that CSPs want to add.
  • Develop an API-powered model for assisted and self-service channels to co-exist.
  • Provide zero-code design-time and prove commercially viable run-time experience.

“CSPs today need partners to elevate their offerings, drive growth, and prepare for the ever more competitive future,” said Keith Sutton, CTO media and communications service line, industry solutions transformation, Microsoft. “Our catalyst project with CSG, Nokia, and Vodafone provides an end-to-end solution that not only lowers costs and shortens time to market but also allows CSPs to be more agile and future-forward in their customer interactions. It is a testament to our collective commitment to help telecom players build new digital marketplaces to thrive and succeed today while driving their future growth.”

TM Forum announced the Catalyst Award winners during Digital Transformation World Asia. Honoring the innovation and impact of its members in the industry, TM Forum acknowledged a total of four Catalyst proof-of-concept projects as ‘Outstanding Catalysts’ for their significant contributions to the acceleration of digital transformation across the industry.

About CSG

CSG empowers companies to build unforgettable experiences, making it easier for people and businesses to connect with, use and pay for the services they value most. Our customer experience, billing and payments solutions help companies of any size make money and make a difference. With our SaaS solutions, company leaders can take control of their future and tap into guidance along the way from our fiercely committed and forward-thinking CSGers around the world.

Want to learn more about how to be a change-maker and industry shaper like our 1,000-plus clients? Visit csgi.com to learn more.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Kristine Østergaard
Public Relations
+44 (0)79 2047 7204
kristine.ostergaard@csgi.com

John Rea
Investor Relations
+1 (210) 687-4409
john.rea@csgi.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye